Zosuquidar

Zosuquidar

Systematic (IUPAC) name
(2R)-​1-​{4-​[(1aR,10bS)-​1,1-​difluoro-​1,1a,6,10b-​tetrahydrodibenzo​[a,e]​cyclopropa​[c]​[7]​annulen-​6-​yl}-​3-​(quinolin-​5-​yloxy)​propan-​2-​ol
Clinical data
Identifiers
CAS Registry Number	167354-41-8 N
ATC code	None
PubChem	CID 153997
ChemSpider	24599682 Y
UNII	AB5K82X98Y Y
KEGG	D06387 Y
ChEMBL	CHEMBL444172 Y
Chemical data
Formula	C32H31F2N3O2
Molecular mass	527.61 g/mol
SMILES Cl.Cl.Cl.FC4(F)[C@@H]3c1ccccc1C(c2c(cccc2)[C@@H]34)N5CCN(CC5)C[C@@H](O)COc7c6cccnc6ccc7
InChI InChI=1S/C32H31F2N3O2/c33-32(34)29-22-7-1-3-9-24(22)31(25-10-4-2-8-23(25)30(29)32)37-17-15-36(16-18-37)19-21(38)20-39-28-13-5-12-27-26(28)11-6-14-35-27/h1-14,21,29-31,38H,15-20H2/t21-,29-,30+,31-/m1/s1  Y Key:IHOVFYSQUDPMCN-DBEBIPAYSA-N  Y
N (what is this?)  (verify)

Zosuquidar is an experimental antineoplastic drug currently under development. It has completed Phase 3 clinical trials in the United States. It inhibits P-glycoproteins. Other drugs with this mechanism include tariquidar and laniquidar. P-glycoproteins are trans-membrane proteins that pump foreign substances out of cells in an ATP dependent fashion. Cancers overexpressing P-glycoproteins are able to pump out therapeutic molecules before they are able to reach their target, effectively making the cancer multi-drug resistant. Zosuquidar inhibits P-glycoproteins, inhibiting the efflux pump and restoring sensitivity to chemotherapeutic agents.

References